Clinical outcomes of intensive vs. less intensive first-line chemotherapy for metastatic colorectal cancer - supplementary material

<strong>Supplementary Materials</strong> <strong>Figure S1. Subgroup analysis of (A) TFST and (B) OS between the IT and LIT groups.</strong> TFST, time to first subsequent therapy; OS, overall survival; IT, intensive therapy; LIT, less-intensive therapy; CI, confidence interval; HR, hazard ratio. <strong>Figure S2. Subgroup analysis of (A) TFST and (B) OS between the with- and without-MTA groups.</strong> TFST, time to first subsequent therapy; OS, overall survival; w/o, without; w/, with; MTA, molecularly targeted agent; CI, confidence interval; HR, hazard ratio. <strong>Figure S3. Subgroup analysis of (A) TFST and (B) OS between the with- and without-BEV groups. </strong>TFST, time to first subsequent therapy; OS, overall survival; w/o, without; w/, with; BEV, bevacizumab; CI, confidence interval; HR, hazard ratio. <strong>Table Supplemental 1.</strong> Patient characteristics and Barthel index scores <strong>Table Supplemental 2.</strong> Patient characteristics in the with- and without-molecularly targeted agent (MTA) subgroups. <strong>Table Supplemental 3.</strong> Patient characteristics in the intensive therapy (IT) and less-intensive therapy (LIT) subgroups.